Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor Edoxaban Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Feb 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edoxaban (Primary) ; Enoxaparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Registrational; Therapeutic Use
Acronyms STARS E-3; STARS E-III

28 Jul 2011 Pooled analysis published in the Journal of Thrombosis and Haemostasis.
12 Aug 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
12 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com